Quantcast
Last updated on April 19, 2014 at 8:45 EDT

Vestagen Completes $8.25 Million Financing To Launch Its Vestex(R) Protective Healthcare Uniforms And Medical Scrubs

August 27, 2013

–Clinically-Proven Approach Integrates Three Technologies to Transform Scrub Uniforms into Medical Devices Providing Active Barrier Protection from Dangerous Contaminants–

ORLANDO, Fla., Aug. 27, 2013 /PRNewswire/ — Vestagen Technical Textiles, Inc., today announced completion of an $8.25 million financing. Vestagen markets Vestex(®), the first in a new class of medical devices based on active barrier protective fabrics that are clinically proven to prevent or reduce the acquisition and retention of contaminants on clothing. Vestex garments are engineered to have robust liquid repellency and antimicrobial properties, along with breathability, comfort and durability. The financing was led by new investor Advent Life Sciences. Alliance Healthcare Investment Fund also participated in the financing, along with founding investor V-Ten Capital and other private investors. Vestagen intends to use the proceeds from the financing to accelerate the commercial launch of medical scrub uniforms and other protective apparel made from its proprietary Vestex fabrics.

Contaminated clothing has been shown in multiple studies to be an important conduit of bacteria to healthcare workers, who have the highest rate of illness of any occupation in the U.S. More than a dozen peer-reviewed studies document the contamination of clothing in healthcare facilities where there are patients infected with resistant organisms such as MRSA and C. difficile. These difficult-to-treat organisms put healthcare workers at risk and are responsible for many of the most serious hospital acquired infections.

In a clinical study published in the Journal of Infection Control and Hospital Epidemiology, researchers reported a statistically significant MRSA reduction of more than 99.99% on the Vestex scrubs compared to standard uniforms. Importantly, this study illustrated that the healthcare workers wearing Vestex had lower levels of microbes present on their garments than on their hands, in contrast with the group wearing the standard scrubs, where the level of contamination on the workers’ hands and scrubs was equal.

“Healthcare workers know to wash their hands between patients, but they cannot easily change their scrubs. We developed Vestex in response to a major unmet need for durable, comfortable, continuous-wear garments that would protect healthcare workers from the potentially dangerous contaminants they encounter on the job every day,” said Uncas “Ben” B. Favret III, president and CEO of Vestagen.

Mr. Favret continued, “Vestex is the first technology-based active barrier fabric engineered to transform scrub uniforms into medical devices that protect healthcare workers and those with whom they come in contact. Our proprietary fluid repellent, antimicrobial and moisture management technologies work together to prevent the acquisition and retention of microbes and other contaminants on healthcare workers’ clothing, while ensuring comfort. The unique protective properties of Vestex scrub uniforms are supported with peer-reviewed clinical data, and we are in the process of filing for FDA clearance as a Class 2 medical device. Initial acceptance by healthcare workers and institutions has been excellent.”

Vestex incorporates three distinct proprietary technologies – a durable fluid barrier technology, an antimicrobial technology and a technology for enhanced wearer comfort. The fluid barrier technology creates a special structured surface that binds to individual fibers, resulting in a fabric that is highly repellent to bodily fluids, water, oil, dirt and dust. This high degree of repellency is designed to work synergistically with Vestagen’s antimicrobial technology, which has been shown to be effective against a broad spectrum of organisms in vitro and is based on a proprietary agent that has never been associated with microbial adaptation or resistance in 25 years of use. Vestex’s third technology acts to wick away moisture from the inside of the fabric, enabling evaporation and creating a cooling effect for wearers while accelerating drying.

“Growing concerns about the human and system-wide costs of hospital acquired infections give healthcare providers, payors, workers and regulators a shared interest in finding solutions,” said Dale Pfost, PhD, a general partner at Advent Life Sciences. “By improving healthcare worker safety, we believe that we can also improve patient safety. Vestex combines three innovative technologies to transform healthcare uniforms from potential sources of contamination into medical devices designed to protect workers and their patients, in the form of everyday work garments that are comfortable, durable and competitively priced.”

Dr. Pfost added, “There are additional applications for Vestex fabrics in other industries where workers are routinely exposed to biological contaminants, and we look forward to supporting the company as it works with multiple partners and regulatory agencies to extend access to this unique set of products.”

In conjunction with the financing, Dr. Pfost is joining the Vestagen Board of Directors as executive chairman, and Joe Mayernik of Alliance Healthcare Investment Fund is joining as a director. James P. Karides, CPA, of V-Ten Capital Partners is continuing as a director.

For more information about Vestagen and Vestex, visit www.vestagen.com and www.vestexprotects.com.

About Vestagen
Vestagen Technical Textiles develops and markets advanced performance textile products and technologies. Vestagen has developed Vestex(®), the first in a new class of technology-based, active barrier protective fabrics combining antimicrobial, liquid repellent and breathability properties. Vestex uniforms and scrubs are designed to protect healthcare workers and their patients from dangerous contaminants. They are clinically proven to prevent or reduce the acquisition and retention of contaminants on clothing and are comfortable, durable and affordable. For more information, visit www.vestagen.com.

About Advent Life Sciences
Advent Life Sciences is the dedicated Life Sciences team at Advent Venture Partners, one of Europe’s best established growth and venture capital firms. Advent Life Sciences invests predominantly in early-stage and growth equity life sciences companies in the UK, Europe and the US. It will back companies that have a first- or best-in-class approach in a range of sectors within the life sciences sector, including new drug discovery, enabling technologies, med-tech and diagnostics. For more information, visit www.adventventures.com.

About Alliance Healthcare Partners Group
Alliance Healthcare Partners Group is focused on building and supporting businesses that can create fundamental and lasting changes in healthcare; so that providers, payers, and clinicians can improve the quality of care with fewer resources. The company’s Investment Fund focuses on innovative technology and service companies that help healthcare providers deliver enhanced efficiency, improved outcomes and lower cost healthcare. The Fund team identifies innovative, high-growth companies that use new approaches and technologies to disrupt the healthcare status quo. For more information, visit www.alliancehcpartners.com.

About V-Ten Capital Partners
V-Ten is a collaborative of experienced investors who provide investment capital for seed, early and growth stage companies that require the invaluable benefit of tried and true to-market strategies, business practices and processes. The V-Ten team has decades of combined experience in leading some of the most diverse companies to the top of their markets. V-Ten’s philosophy is to invest in breakthrough companies and to structure each investment collaboratively with exceptional management teams to build superior long-term value. V-Ten was founded by Richard Sharp who was responsible for the success of many iconic American businesses in the last 25 years, including: Circuit City, CarMax, Flextronics International and Crocs. For more information, visit www.vtencp.com.

    Contacts:
    ---------

    Vestagen                     Media:

    Ben Favret BLL Partners, LLC
     President & CEO             Barbara Lindheim

    ben.favret@vestagen.com                                   +1 212 584-2276

                                 blindheim@bllbiopartners.com

SOURCE Vestagen Technical Textiles, Inc.


Source: PR Newswire